BC Platforms Flags Evidence Integrity Gap as Core Barrier to AI-Driven Drug Development

Regulatory submissions built on AI-generated outputs are only as defensible as the evidence architecture behind them, and according to BC Platforms contributor Narasimha Kumar, that architecture is where the industry is currently failing. Writing in MedCity News, Kumar argues that the pharmaceutical sector's AI problem is not one of data volume but of evidence quality: specifically, the loss of semantic context, clinical meaning, and temporal relationships when data is aggregated for model input.

The distinction carries direct consequences for regulatory affairs teams preparing AI-assisted dossiers. Fragmented data pipelines, drawing from electronic health records, imaging archives, genomic repositories, pathology systems, and patient registries, routinely strip the relational context that regulators expect to see preserved in evidence packages. Kumar's position is that AI cannot reliably convert this fragmented input into trusted scientific conclusions without what he terms connected evidence networks: integrated structures that maintain multimodal relationships and clinical sequencing across the full patient journey.

For QA directors and regulatory leads, the operational read is grounded in existing frameworks. ICH Q10 and data integrity expectations under 21 CFR Part 11 already require that records be attributable, legible, contemporaneous, original, and accurate. Applying those standards to AI-generated evidence packages demands that the upstream data architecture, not just the model output, can withstand scrutiny. If semantic context is lost before the model is trained, no post-hoc documentation corrects the evidentiary gap at submission.

Kumar's argument aligns with the FDA's evolving posture on AI in drug development, which has increasingly focused on the provenance and traceability of AI-generated findings rather than the computational methods alone. Real-world data and patient-generated inputs, both cited in the piece as high-volume but structurally inconsistent sources, represent a particular pressure point: their clinical utility depends on contextual preservation that most current ingestion pipelines do not guarantee.

The piece is part of a broader body of work from Kumar that includes analysis of real-world data in trial design, published in MedNous, and an examination of interoperability barriers to AI adoption in pharma, published in Bio-IT World, both of which reinforce the same foundational argument: data volume is not the constraint; trusted, cross-border evidence ecosystems are.

As FDA guidance on AI-assisted submissions continues to develop, the measurable checkpoint for regulatory teams will be whether their data governance frameworks can demonstrate semantic integrity from source system to evidence package.

Source: BC Platforms via bcplatforms.com, August 11, 2026. Original opinion piece by Narasimha Kumar published in MedCity News.